NAD+: Cellular Energy Coenzyme in Aging and Metabolic Research

What Is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme found in every living cell, functioning as a critical mediator of energy metabolism and cellular signaling. NAD+ participates in hundreds of enzymatic reactions as an electron carrier, accepting electrons during catabolism and donating them to drive ATP synthesis through oxidative phosphorylation. Beyond its classical metabolic role, NAD+ is now recognized as a central regulator of aging, genome stability, circadian rhythms, and cellular stress responses.

For dosing, reconstitution, and protocol details, see our NAD+ Dosage Protocol Guide: IV, Subcutaneous & Reconstitution for Research 2026.

NAD+ exists in two interconvertible redox forms: the oxidized form (NAD+) and the reduced form (NADH). The ratio of NAD+ to NADH (the NAD+/NADH ratio) is a fundamental indicator of cellular metabolic state — high NAD+ indicates an oxidized, energy-deficient state that activates energy-generating pathways, while high NADH indicates reduced, energy-replete conditions. This ratio serves as a master metabolic sensor that coordinates cellular responses to nutritional status.

Biochemistry and Molecular Biology

Chemical Structure

NAD+ is a dinucleotide consisting of two nucleosides (adenine and nicotinamide mononucleotide) joined by a pyrophosphate bridge:

• •Nicotinamide mononucleotide (NMN): Nicotinamide riboside (NR) + phosphate group; the portion that carries electrons
• •Adenosine monophosphate (AMP): Provides structural stability and binding specificity for enzymes
• •Molecular formula: C₂₁H₂₇N₇O₁₄P₂
• •Molecular weight: 663.43 Da
• •CAS number: 53-84-9

NAD+ Biosynthesis Pathways

NAD+ is synthesized through multiple converging pathways:

De Novo Pathway (Kynurenine pathway): Converts dietary tryptophan through multiple enzymatic steps to quinolinic acid, which is then converted to NAMN and ultimately NAD+. This is the metabolically costly primary biosynthesis route and explains why tryptophan has modest NAD+ precursor activity.

Preiss-Handler Pathway: Converts niacin (nicotinic acid) to NAMN via NaPRT, then through NADT and NADS to produce NAD+. Dietary niacin primarily enters this pathway.

Salvage Pathway (most active): Converts nicotinamide (Nam) — the breakdown product of NAD+ consuming enzymes — back to NMN via NAMPT (nicotinamide phosphoribosyltransferase), then to NAD+ via NMNAT. This recycling pathway is the primary mechanism for maintaining cellular NAD+ levels under normal conditions.

NR/NMN Pathways: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are direct NAD+ precursors that bypass NAMPT, the rate-limiting step in the salvage pathway. Both are being intensively studied as supplements to boost NAD+ levels.

NAD+-Dependent Enzymes

Sirtuins (SIRT1-7)

Sirtuins are NAD+-dependent deacylases that couple NAD+ hydrolysis to removal of acyl modifications (most commonly acetyl groups) from lysine residues on proteins. Seven mammalian sirtuins (SIRT1-7) have been identified, with subcellular localizations spanning the nucleus, cytoplasm, and mitochondria.

Key sirtuin research targets:

• •SIRT1: Nuclear; deacetylates histones (H3K9ac, H4K16ac) and transcription factors (p53, NF-κB, PGC-1α, FOXO). Central regulator of metabolism, DNA repair, and aging. Most studied sirtuin.
• •SIRT2: Cytoplasmic; regulates tubulin acetylation and mitotic checkpoint. Implicated in Parkinson's disease and cancer.
• •SIRT3: Mitochondrial matrix; major regulator of mitochondrial protein acetylation. Activates oxidative phosphorylation and fatty acid oxidation enzymes.
• •SIRT4: Mitochondrial; ADP-ribosyltransferase; regulates amino acid metabolism and mitochondrial biogenesis.
• •SIRT5: Mitochondrial intermembrane space; demalonylase, desuccinylase; regulates urea cycle enzymes.
• •SIRT6: Nuclear; deacetylates H3K9ac at telomeres and DNA repair loci; central to genomic stability and DNA repair.
• •SIRT7: Nucleolar; regulates rRNA synthesis and ribosome biogenesis.

SIRT1 and SIRT3 are the most extensively studied in the context of aging and metabolic health. Their NAD+ dependence means that declining NAD+ levels with age directly impair sirtuin activity, creating a mechanistic explanation for age-related physiological deterioration.

PARPs (Poly-ADP Ribose Polymerases)

PARPs are a family of 17 enzymes (PARP1-17) that consume NAD+ to produce poly-ADP-ribose (PAR) or mono-ADP-ribose (MAR) modifications on proteins. PARP1 is the major consumer of NAD+ in cells, responsible for detecting and repairing DNA strand breaks.

PARP1 is activated by DNA damage, where it synthesizes PAR chains on histones and itself to recruit DNA repair machinery. While essential for genome maintenance, excessive PARP1 activation (as in severe genotoxic stress) can deplete cellular NAD+ to levels that compromise sirtuin activity and energy metabolism.

This competitive consumption of NAD+ by PARPs vs. sirtuins creates an important research paradigm: DNA damage-induced PARP activation depletes NAD+, reducing sirtuin activity, impairing metabolic regulation, and potentially accelerating cellular aging. PARP inhibitors (clinical cancer drugs) protect NAD+ levels by reducing PARP1-mediated consumption.

CD38 and CD157

CD38 is an ectoenzyme widely expressed on immune cells, neurons, and other tissues that catalyzes NAD+ hydrolysis to produce cyclic ADP-ribose (cADPR), ADPR, and nicotinamide. CD38 is a major catabolic enzyme for NAD+ and its activity increases with age, contributing significantly to the age-related decline in NAD+ levels.

Research has demonstrated that:

• •CD38 knockout mice have dramatically higher tissue NAD+ levels than wild-type controls
• •CD38 levels increase with age and inflammation
• •CD38 inhibitors (flavonoids like apigenin and quercetin; specific small molecules) raise NAD+ levels and recapitulate some metabolic benefits of NAD+ precursors
• •Inflammatory signaling (NF-κB activation) upregulates CD38 expression, creating a feedback loop where inflammation depletes NAD+ and impairs sirtuin-mediated resolution of inflammation

NAD+ Decline with Aging

One of the most significant findings in aging biology over the past decade is the consistent, multi-organ decline in NAD+ levels with age. Multiple independent research groups have documented 40-60% reductions in NAD+ content in tissues including skeletal muscle, liver, brain, and adipose tissue in aged mammals compared to young controls.

Mechanisms of Age-Related NAD+ Decline

Multiple mechanisms converge to reduce NAD+ with aging:

1. Reduced biosynthesis: NAMPT (the rate-limiting enzyme in the salvage pathway) expression decreases with age in multiple tissues, reducing NAD+ production capacity

2. Increased CD38 activity: Age-related elevation of CD38 expression (driven partly by chronic low-grade inflammation) accelerates NAD+ catabolism

3. Increased DNA damage: Accumulating DNA damage with age activates PARP1, depleting NAD+ through repair processes

4. Reduced mitophagy and mitochondrial quality: Impaired mitochondrial turnover reduces the capacity for efficient NAD+/NADH cycling

5. Chronic inflammation: NF-κB-driven CD38 expression creates a feed-forward cycle of inflammation → NAD+ depletion → reduced sirtuin anti-inflammatory activity → more inflammation

Consequences of Low NAD+ in Aging

The decline in NAD+ affects virtually every aspect of cellular and organismal physiology:

• •Mitochondrial dysfunction: Reduced SIRT3 activity impairs mitochondrial enzyme acetylation status and function
• •DNA repair deficiency: Reduced PARP1 substrate availability impairs DNA damage response
• •Circadian disruption: SIRT1/SIRT6 activity in the CLOCK/BMAL1 transcriptional machinery requires NAD+
• •Muscle wasting (sarcopenia): Low NAD+ impairs mitochondrial function and SIRT1-mediated muscle gene regulation
• •Cognitive decline: Neuronal NAD+ depletion impairs SIRT1/SIRT3-dependent neuroprotective mechanisms
• •Metabolic syndrome: Impaired SIRT1/AMPK crosstalk disrupts glucose and lipid homeostasis

NAD+ Precursors in Research

Nicotinamide Riboside (NR)

NR is a pyridine-nucleoside form of vitamin B3 that enters the NAD+ salvage pathway at NMN, bypassing NAMPT. NR has been shown to raise blood and tissue NAD+ levels in rodents and humans in controlled studies. Research highlights include:

• •Elevation of NAD+ in multiple tissues in rodents, with metabolic benefits in obese and aged models
• •First human study demonstrating effective oral NAD+ elevation (Trammell et al., Nature Communications 2016)
• •Multiple safety studies in humans at doses up to 2000 mg/day showing favorable tolerance

Nicotinamide Mononucleotide (NMN)

NMN is the direct precursor to NAD+ and is converted to NAD+ by NMNAT enzymes. Research findings include:

• •Rapid conversion to NAD+ after oral administration in rodent models
• •Metabolic, cardiovascular, and cognitive benefits in aged rodents
• •First human clinical trial (Irie et al., 2020) demonstrating oral bioavailability and blood NAD+ elevation
• •Ongoing clinical research for muscle function in aging and cardiovascular outcomes

Nicotinamide (Nam) and Niacin (NA)

Both are classical B3 vitamins and NAD+ precursors:

• •Nicotinamide: Enters the salvage pathway via NAMPT; most common dietary source; high doses may saturate NAMPT and potentially inhibit sirtuins as a byproduct
• •Niacin (Nicotinic Acid): Enters via the Preiss-Handler pathway; causes "niacin flush" (prostaglandin-mediated skin flushing); proven cardiovascular benefits at pharmacological doses

Research Applications

Aging and Longevity Models

NAD+ augmentation strategies have been tested across a range of aging model systems:

C. elegans: NAD+ precursor supplementation extends lifespan and healthspan, partly through sir-2.1 (SIRT1 homolog) activation. These findings provided early evidence for NAD+-sirtuin-longevity connections.

Drosophila: Elevated NAD+ extends lifespan and improves age-related locomotor decline, with effects dependent on Sir2 (sirtuin) activity.

Rodent models: Multiple studies demonstrate that NAD+ precursor supplementation in aged mice improves:

• •Glucose tolerance and insulin sensitivity
• •Muscle strength and endurance
• •Cognitive performance
• •Cardiovascular function
• •Reduced age-related inflammatory markers
• •Partial restoration of young-like gene expression profiles

Notable landmark studies:

• •Gomes et al. (Cell, 2013): NMN administration restored young-like muscle mitochondrial homeostasis in aged mice through SIRT1-mediated mechanisms
• •Yoshino et al. (Cell Metabolism, 2011): NMN supplementation in diet-induced obesity/diabetic mice restored metabolic parameters
• •Mills et al. (Cell Metabolism, 2016): Long-term NMN administration in aging mice reversed multiple age-related physiological declines

Metabolic Disease Research

NAD+ research has strong applications in metabolic disease:

• •Type 2 diabetes: NAD+ precursors improve insulin sensitivity and beta-cell function in multiple rodent models
• •Obesity: NAMPT overexpression or NAD+ supplementation reduces fat accumulation in high-fat diet models
• •NAFLD: NAD+ augmentation reduces hepatic fat accumulation through SIRT1-mediated effects on lipid metabolism genes
• •Metabolic syndrome: NAD+ acts upstream of multiple metabolic disease pathways through sirtuin regulation

Neurological Research

NAD+ depletion is increasingly recognized as a contributor to neurodegeneration:

• •Alzheimer's disease: NAD+ augmentation reduces amyloid and tau pathology in AD mouse models
• •Parkinson's disease: SIRT2 inhibition (conserving NAD+ for other sirtuins) protects against alpha-synuclein toxicity
• •Traumatic brain injury: NAD+ precursors reduce neuronal death and improve recovery in TBI models
• •ALS: NAD+ augmentation extends lifespan and delays disease onset in ALS mouse models
• •Peripheral neuropathy: SIRT1 activation through NAD+ protects peripheral neurons from chemotherapy-induced damage

DNA Repair and Genome Stability Research

The PARP-NAD+ axis makes NAD+ central to DNA damage research:

• •PARP inhibitors (clinical BRCA cancer drugs) represent NAD+-sparing strategies
• •NAD+ augmentation improves DNA repair capacity in aged cells
• •SIRT6 (NAD+-dependent) is a critical telomere maintenance enzyme
• •NAD+ levels regulate the DNA damage response through both PARP activity and sirtuin-mediated chromatin remodeling

NAD+ and Circadian Rhythms

NAD+ is both a product of and regulator for circadian clock function:

• •NAMPT (the rate-limiting NAD+ biosynthesis enzyme) is transcriptionally controlled by CLOCK:BMAL1, generating circadian NAD+ oscillations
• •Cellular NAD+ oscillates with a ~24-hour period driven by the circadian clock
• •SIRT1 deacetylates and regulates BMAL1 and PER2 in a NAD+-dependent manner, creating a feedback loop between NAD+ and circadian timing
• •Disruption of circadian NAD+ rhythms by shift work or blue-light exposure may contribute to metabolic dysfunction

Research Specifications

• •Molecular weight: 663.43 Da (free acid)
• •Molecular formula: C₂₁H₂₇N₇O₁₄P₂
• •CAS number: 53-84-9
• •Available forms: Lyophilized powder, solution
• •Stability: Unstable in aqueous solution at neutral-alkaline pH; more stable at pH 5-6; store solutions at -20°C
• •Storage: -20°C (lyophilized), protect from light and moisture
• •Classification: Biochemistry reagent; for laboratory research use

Related Research Compounds

Researchers studying NAD+ pathways may find synergy with:

• •MOTS-c — mitochondrial peptide acting through converging metabolic pathways (AMPK, folate cycle)
• •Methylene Blue — mitochondrial electron carrier with overlapping neuroprotective applications
• •Visfatin/eNAMPT (NAMPT) — the rate-limiting NAD+ salvage-pathway enzyme, also studied as an adipokine and cancer driver
• •Klotho (α-Klotho) — anti-aging longevity protein studied alongside NAD+ pathways in kidney, cardiovascular, and neuroprotection research

NAD+ represents one of the most fundamental molecules in aging and metabolic research, with implications spanning from basic biochemistry to translational medicine in age-related diseases.

NAD+ Supplier Pricing Comparison (Live Data — 2026)

Pricing for NAD+ research material varies enormously by formulation (buffered vial, bulk powder, nasal spray) and batch size. The table below reflects live listings tracked by Peptides.SO from 61 active suppliers.

Price range: $0.08–$280/mg across 61 tracked suppliers, with the low end reflecting bulk lyophilized powder and the high end reflecting small-batch or specialty-format (spray, injection) listings. Because NAD+ is sold in both bulk-research and specialty-delivery formats, always compare like-for-like: a $/mg bulk powder price is not directly comparable to a pre-formulated spray or injection.

> Research Use Only. All listed material is sold strictly for laboratory research purposes. Not for human or animal administration.

See the NAD+ peptide page for real-time pricing, current stock status, and supplier comparison across all active listings.

Frequently Asked Questions

Does NAD+ really decline with age, and by how much?

Yes — this is one of the most consistently replicated findings in aging biology. A 2021 review in Nature Reviews Molecular Cell Biology (Covarrubias et al.) synthesized evidence across rodent tissues and human blood/skin/muscle showing that NAD+ levels fall substantially from young adulthood through old age, and links this decline mechanistically to reduced sirtuin activity, impaired DNA repair capacity, and several aging-associated conditions including metabolic dysfunction and cognitive decline. The magnitude and tissue-specificity of decline remains an active research question, which is part of why NAD+ precursor supplementation is such a heavily studied intervention.

Do NAD+ precursors like NR and NMN actually raise NAD+ levels, or is that unproven in humans?

Both animal and human data exist, though the human evidence is newer and more limited than the animal literature. Cantó et al. (2012, Cell Metabolism) showed that nicotinamide riboside (NR) raises NAD+ in mouse tissue and activates SIRT1/SIRT3, improving mitochondrial oxidative metabolism and protecting against diet-induced obesity. On the human side, a randomized placebo-controlled trial by Yoshino et al. (2021, Science) found that 10 weeks of oral nicotinamide mononucleotide (NMN) improved skeletal-muscle insulin sensitivity and insulin signaling in postmenopausal women with prediabetes — one of the more rigorous human RCTs in this space to date.

What's the practical difference between NAD+, NMN, and NR for research purposes?

NAD+ is the mature coenzyme itself; NMN and NR are biosynthetic precursors one and two enzymatic steps upstream, respectively. NAD+ has poor cell-membrane permeability compared to its precursors, which is part of why much of the supplementation research focuses on NMN/NR rather than NAD+ itself — the precursors are thought to cross into cells more efficiently before being converted intracellularly. See the site's dedicated NAD+ vs NMN comparison guide for a detailed side-by-side.

How does NAD+ status affect DNA repair research?

NAD+ is the obligate substrate for PARP1, the primary sensor/repair enzyme for single-strand DNA breaks. Wilk et al. (2020, Scientific Reports) demonstrated that boosting extracellular/intracellular NAD+ enhances PARP-dependent DNA repair capacity, and that reduced NAD+ availability suppresses recruitment of the repair protein XRCC1 to damage sites. This is a key mechanistic link researchers cite when studying genome-stability decline in aging models.

Which NAD+-dependent enzyme family is most relevant to longevity research — sirtuins or PARPs?

Both compete for the same finite NAD+ pool, which is part of the mechanistic argument for age-related NAD+ decline mattering functionally. Sirtuins (SIRT1-7) are generally the focus of metabolic/longevity research (mitochondrial biogenesis, circadian regulation, stress resistance), while PARPs dominate genotoxic-stress and DNA-repair research. Some researchers frame chronic PARP activation (e.g., from accumulated DNA damage with age) as a mechanism that depletes NAD+ available to sirtuins — an area of active investigation rather than settled consensus.

How should NAD+ be handled and stored for research use?

NAD+ is unstable in aqueous solution, particularly at neutral-to-alkaline pH, where it degrades relatively quickly. Solutions are more stable at pH 5-6 and should be stored at -20°C, used promptly after reconstitution, and protected from repeated freeze-thaw cycles. Lyophilized powder should be kept at -20°C, protected from light and moisture, until reconstitution.

Key Research Citations

1. Covarrubias AJ, Perrone R, Longo VD, Verdin E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol, 22(2):119-141. PMID: 33353981

2. Cantó C, et al. (2012). The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab, 15(6):838-847. PMID: 22682224

3. Yoshino M, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547):1224-1229. PMID: 33888596

4. Chen SH, et al. (2020). Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity. Sci Rep, 10:734. PMID: 31959836

---

Research Suppliers: Where to Source NAD+ (2026)

NAD+ is available as lyophilized powder in various gram-scale quantities from research suppliers. Price-per-mg varies substantially with quantity; bulk purchasing offers the lowest unit cost. The following prices are from the Peptides.SO live listings database.

Data sourced from Peptides.SO live listings; prices subject to change. NAD+ is for in vitro and research laboratory use only.

> Compare all NAD+ offers → peptides.so/peptide/nad-plus | Price Comparison Tool

---

Frequently Asked Questions: NAD+ Research

Q: What is the rate-limiting step in NAD+ biosynthesis in mammalian cells?

The salvage pathway (the dominant NAD+ synthesis route in most mammalian tissues) is rate-limited by NAMPT (nicotinamide phosphoribosyltransferase), which converts nicotinamide to NMN. NAD+ synthetase (NADSYN1) and NMNAT (nicotinamide mononucleotide adenylyltransferase) isoforms downstream are generally not rate-limiting. This makes NAMPT expression and activity the primary lever controlling intracellular NAD+ abundance, a fact that motivates study of NAMPT activators and of NMN/NR as salvage-pathway bypass substrates.

Q: How does PARP1 activation during DNA damage deplete cellular NAD+?

PARP1 consumes NAD+ to synthesize poly(ADP-ribose) (PAR) chains on target proteins including histones, PARP1 itself, and DNA repair factors, releasing nicotinamide in the process. Under conditions of extensive DNA damage (oxidative stress, radiation), PARP1 can become hyperactivated, consuming NAD+ faster than the salvage pathway can replenish it, collapsing the NAD+/NADH ratio and impairing glycolytic and mitochondrial ATP production — a process historically termed "PARP-mediated cell death" or parthanatos.

Q: What is the conceptual difference between NAD+ as a cofactor and NAD+ as a substrate?

As a cofactor (in oxidoreductases — complex I, LDH, GAPDH, etc.), NAD+/NADH cycles between oxidized and reduced forms without net consumption — the pool is regenerated. As a substrate (for PARPs, sirtuins, CD38, SARM1), NAD+ is cleaved, yielding nicotinamide and an ADP-ribosyl product; the NAD+ molecule is consumed. The latter class of reactions constitutes the main sink for the cellular NAD+ pool and determines why supplementation or NAD+-precursor provision matters in aging and stress contexts.

Q: Why does CD38 upregulation with aging matter for NAD+ biology?

CD38 is a hydrolase that cleaves NAD+ to ADPR (and cyclic ADPR). CD38 expression increases markedly in multiple tissues during aging, largely driven by accumulation of senescent cells and age-associated inflammation (SASP). Because CD38 has a Km for NAD+ that is in the physiologically relevant range, its increased activity in aged tissues is considered a major driver of age-related NAD+ decline, potentially more significant than decreased NAMPT activity.

Q: How is extracellular NAD+ taken up by cells, and is direct supplementation of NAD+ in culture effective?

Cells lack efficient direct transporters for intact NAD+. Extracellular NAD+ is cleaved by ectonucleotidases (CD38, CD73, ENPP1) to NMN and NR, which enter cells via specific transporters (Slc12a8 for NMN in some tissues; equilibrative nucleoside transporters for NR). In cell culture, exogenous NAD+ addition is largely effective via this extracellular cleavage/transport axis, not by direct NAD+ import, which has implications for interpreting dose-response relationships in supplementation studies.

Q: What key variables should be controlled in NAD+ measurement experiments?

NAD+ is highly labile ex vivo: samples must be extracted immediately on ice with perchloric acid or methanol:water. Freeze-thaw cycles degrade it rapidly. Cycling assays (enzymatic) and LC-MS/MS are the most validated quantification methods; fluorescence-based methods require careful calibration. Importantly, NAD+ levels differ dramatically by subcellular compartment (cytosol, mitochondria, nucleus) and tissue type, so whole-cell or tissue homogenate measurements represent a composite that can obscure compartment-specific dynamics.

---

Further Reading:

• •MOTS-c: Mitochondrial-Derived Peptide for Metabolic Homeostasis Research
• •5-Amino-1MQ: NNMT Inhibitor for Metabolic and Obesity Research
• •Tesofensine: Triple Monoamine Reuptake Inhibitor for Metabolic Research
• •Apelin Peptides and the APJ Receptor: The Apelinergic System in Cardiovascular, Metabolic, and Aging Research
• •Dosage Chart
• •Price Comparison